Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.
Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.
Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.
Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.
Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.
Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.
A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.
The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.
The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.